Fig 4 - available via license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Content may be subject to copyright.
Pathological specimen. A. Well-differentiated sebaceous carcinoma composed of lobules and sheets of tumor cells with central necrosis (40 X). B. Individual cells have distinct cell membranes, clear to vacuolated cytoplasm, vesicular nuclei with prominent nucleoli and mitotic figures (400X).
Source publication
Sebaceous-gland carcinoma can occur alone or as one of the defining features of the Muir-Torre syndrome. Cases occurring below the head and neck are extremely rare. Here we describe the case of a 70-year-old male with Muir-Torre syndrome who had a recurrent sebaceous-gland carcinoma in the left lower extremity that demonstrated 18F-FDG avidity. An...
Citations
... As illustrated in our case, cutaneous lesions can be diffusely found and recurrent, while visceral tumors can be numerous, arise from multiple organ systems (gastrointestinal, urinary, reproductive), and can recur with poor outcomes. Whole body [ 18 F] FDG PET/CT appears useful and superior to computed tomography in the diagnosis and follow-up of MTS, particularly in identifying less conspicuous cutaneous tumors and MTS-associated internal malignancies [4][5][6]. ...
Background:
Extraocular sebaceous carcinoma (EOSC) is an aggressive malignancy of the sebaceous gland. Surgery is considered the cornerstone of treatment, but there is lack of clarity about extent and adjuvant treatment.
Methods:
We conducted a systematic review and analysis of individual patient data of all published cases of EOSC to look into demography, pattern of care, importance of type of surgery, and other adjuvant treatment and survival outcome. A search of PubMed and Google Scholar was done with the key words sebaceous carcinoma, extraocular sebaceous carcinoma, and Muir-Torre syndrome till December 2017. The data were compiled in an Excel chart and analyzed using SPSS IBM software.
Results:
Data of 206 patients were retrieved. Median age at presentation was 65 years (range: 11-96 years). Surgery was performed in all except 13 patients. Of these 13, eight were deemed inoperable for extensive disease, and five had metastatic disease. Median PFS and OS for the entire cohort were 84 months (95% CI: 10-158 months) and 92 months (95% CI: 59-126 months). Univariate analysis revealed significantly poor survival for patients with a metastatic disease, regional nodal metastasis, and those with Mohs micrographic or incomplete surgery.
Conclusion:
EOSC is a disease of elderly patients with good prognosis. Complete surgery with regional lymph node dissection is standard treatment. The role of adjuvant radiotherapy is debatable but can be considered in patients with incomplete surgery or high-risk factors.
